Expanding the Scope of Ama: A Systems Biology Framework for Metabolic and Immune Disorders

Abstract BACKGROUND: The Ayurvedic concept of Ama refers to the accumulation of incompletely digested or metabolized substances in the body due to impaired Agni (digestive fire). Ama is described as a pathological entity that disrupts systemic homeostasis, leading to chronic metabolic and immune disorders. Modern medical science recognizes similar pathological processes, such as endotoxin accumulation, gut dysbiosis, metabolic endotoxemia, and inflammatory responses driven by advanced glycation end-products (AGEs), damage-associated molecular patterns, and oxidative stress. Despite advances in research and clinical interventions, metabolic and immune disorders like diabetes, metabolic dysfunction-associated fatty liver disease, inflammatory bowel disease, and autoimmune conditions continue to rise globally. Expanding the scope of Ama and its subtypes in relation to these disorders may provide novel insights for disease prevention, diagnostics, and therapeutic approaches. EXISTING KNOWLEDGE AND GAP: Ayurvedic texts elaborate on Ama as a primary etiological factor in disease progression, classifying it based on its origins, affinity, and systemic translocation. However, there is a lack of standardized clinical assessment tools to evaluate Ama in the context of modern disease models. Current biomedical research highlights the crucial role of gut health, intestinal permeability, microbial dysbiosis, and metabolic endotoxemia in the development of chronic diseases. Despite these parallels, there is minimal integrative research correlating Ama with measurable biochemical or molecular markers. Moreover, the role of Ama in immune activation and inflammatory disorders remains largely unexplored within a scientific framework. PROPOSED CONCEPT: This paper proposes an expanded classification of Ama , integrating Ayurvedic epistemology with modern biomedical understanding. Ama can be characterized as a gut-derived response antigen complex or gut-associated molecular complex, which includes toxic metabolites, undigested peptides, microbial toxins, and inflammatory mediators resulting from impaired digestion and absorption. The subtypes of Ama can be categorized based on the site of expression, cause of origin, specificity or affinity, Kaal , and its movement or translocation. Modern tools such as metabolomics, proteomics, transcriptomics, and computational systems biology models can be employed to validate Ama and its subtypes. Biomarkers such as HbA1c (paralleling Ama in diabetes), lipid oxidation markers, gut microbiome alterations, and inflammatory cytokines may serve as objective correlates of Ama . WAY FORWARD: Future research should focus on developing standardized clinical scales for Ama assessment, incorporating radiological, biochemical, molecular, and genetic markers. Systems biology approaches, such as network pharmacology and artificial intelligence-based predictive models, should be utilized to map the progression of Ama in metabolic and immune disorders. Ayurvedic interventions, such as Deepana, Pachana , and Shodhana therapies, should be studied for their impact on gut barrier function, microbiome modulation, and immune homeostasis. Bridging Ayurvedic concepts with modern scientific methodologies will enable the development of personalized diagnostic and therapeutic strategies for chronic diseases.